411 related articles for article (PubMed ID: 31367943)
1. A comprehensive review of rituximab therapy in rheumatoid arthritis patients.
Tavakolpour S; Alesaeidi S; Darvishi M; GhasemiAdl M; Darabi-Monadi S; Akhlaghdoust M; Elikaei Behjati S; Jafarieh A
Clin Rheumatol; 2019 Nov; 38(11):2977-2994. PubMed ID: 31367943
[TBL] [Abstract][Full Text] [Related]
2. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature.
Raghavan P; Sreenath S; Cherian S; Shenoy PD
Clin Rheumatol; 2019 Sep; 38(9):2399-2402. PubMed ID: 31076945
[TBL] [Abstract][Full Text] [Related]
4. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
5. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis.
Lindenberg L; Spengler L; Bang H; Dorner T; Maslyanskiy AL; Lapin SV; Ilivanova EI; Martinez-Gamboa L; Bastian H; Wittenborn E; Egerer K; Burmester GR; Feist E
Arthritis Res Ther; 2015 Aug; 17(1):206. PubMed ID: 26268352
[TBL] [Abstract][Full Text] [Related]
6. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis].
Quartuccio L; Salvin S; Saracco M; Lombardi S; Fabris M; Mansutti E; Maset M; Pellerito S; De Vita S
Reumatismo; 2009; 61(3):182-6. PubMed ID: 19888503
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
[TBL] [Abstract][Full Text] [Related]
8. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in routine care of severe active rheumatoid arthritis : A prospective, non-interventional study in Germany.
Krause A; Aries PM; Berger S; Fiehn C; Kellner H; Lorenz HM; Meier L; Müller GA; Müller-Ladner U; Schwarting A; Tony HP; Peters MA; Wendler J
Z Rheumatol; 2019 Nov; 78(9):881-888. PubMed ID: 30276727
[TBL] [Abstract][Full Text] [Related]
11. High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.
Gardette A; Ottaviani S; Tubach F; Roy C; Nicaise-Roland P; Palazzo E; Gill G; Meyer O; Dieudé P
Joint Bone Spine; 2014 Oct; 81(5):416-20. PubMed ID: 24998790
[TBL] [Abstract][Full Text] [Related]
12. Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.
den Broeder AA; Verhoef LM; Fransen J; Thurlings R; van den Bemt BJF; Teerenstra S; Boers N; den Broeder N; van den Hoogen FHJ
Trials; 2017 Aug; 18(1):403. PubMed ID: 28854956
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
[TBL] [Abstract][Full Text] [Related]
14. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.
Sellam J; Rivière E; Courties A; Rouzaire PO; Tolusso B; Vital EM; Emery P; Ferraccioli G; Soubrier M; Ly B; Hendel Chavez H; Taoufik Y; Dougados M; Mariette X
Arthritis Res Ther; 2016 Dec; 18(1):294. PubMed ID: 27964756
[TBL] [Abstract][Full Text] [Related]
15. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
[TBL] [Abstract][Full Text] [Related]
16. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
[TBL] [Abstract][Full Text] [Related]
18. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
Fabris M; Quartuccio L; Lombardi S; Benucci M; Manfredi M; Saracco M; Atzeni F; Morassi P; Cimmino MA; Pontarini E; Fabro C; Pellerito R; Sarzi-Puttini P; Cutolo M; Carletto A; Bambara LM; Fischetti F; Curcio F; Tonutti E; De Vita S
Reumatismo; 2010; 62(4):253-8. PubMed ID: 21253618
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.
Magnusson M; Brisslert M; Zendjanchi K; Lindh M; Bokarewa MI
Rheumatology (Oxford); 2010 Oct; 49(10):1911-9. PubMed ID: 20547657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
